Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

  • Technology appraisal guidance
  • TA429
  • Published: 
Download guidance (PDF)

3 Evidence

The appraisal committee considered evidence submitted by Janssen and a review of this submission by the evidence review group. See the committee papers for full details of the evidence.